PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25117183-1	2014	BACKGROUND AND OBJECTIVE: Vandetanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) signalling, indicated for the treatment of medullary thyroid cancer.	vandetanib	26-36	epidermal growth factor receptor	Homo sapiens	118-150	
25117183-1	2014	BACKGROUND AND OBJECTIVE: Vandetanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) signalling, indicated for the treatment of medullary thyroid cancer.	vandetanib	26-36	epidermal growth factor receptor	Homo sapiens	111-115	
though the cell volume decreased markedly.	metsulfuron methyl	39-42	RNA binding region (RNP1, RRM) containing 3	Homo sapiens	19-22